DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Combining Subjective and Objective Methods for Quantifying Contact Rates and Mixing Pattern in School-Aged Children, Funding Opportunity Announcement (FOA), CK11–006, Initial Review

In accordance with Section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the aforementioned meeting:

Time and Date: 8 a.m.–5 p.m., May 3, 2011 (Closed).

Place: Sheraton Gateway Hotel Atlanta Airport, 1900 Sullivan Road, Atlanta, Georgia 30337. Telephone: (770) 997–1100.

Status: The meeting will be closed to the public in accordance with provisions set forth in Section 552b(c)(4) and (6), Title 5 U.S.C., and the Determination of the Director, Management Analysis and Services Office, CDC, pursuant to Public Law 92–463.

Matters To Be discussed: The meeting will include the initial review, discussion, and evaluation of applications received in response to “Combining Subjective and Objective Methods for Quantifying Contact Rates and Mixing Pattern in School-Aged Children, FOA CK11–006.”

Contact Person For More Information: Gregory Anderson, M.S., M.P.H., Scientific Review Officer, CDC, 1600 Clifton Road, NE., Mailstop E60, Atlanta, Georgia 30333. Telephone: (404) 498–2293. The Director, Management Analysis and Services Office, has delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Dated: February 25, 2011.

Elaine L. Baker,
Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. 2011–6641 Filed 3–21–11; 8:45 am]
BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Statement of Organization, Functions, and Delegations of Authority

Part C (Centers for Disease Control and Prevention) of the Statement of Organization, Functions, and Delegations of Authority of the Department of Health and Human Services (45 FR 67772–76, dated October 14, 1980, and corrected at 45 FR 69296, October 20, 1980, as amended most recently at 76 FR 1167, dated January 7, 2011) is amended as follows: Delete in its entirety the title for the Knowledge Management Branch (CPGBB), within the Division of Laboratory Policy and Practice (CPGB), Laboratory Science Policy and Practice Program Office (CPG), Office of Surveillance, Epidemiology and Laboratory Services (CP) and insert the Technology Management Branch (CPGBB).

Following the title and functional statement for the Laboratory Policy Branch (CPGBC), insert the following: Laboratory Branch (CPGBD).

(1) Provides advanced laboratory training to maintain a competent, prepared, and sustainable national/global laboratory workforce; (2) analyzes, designs, develops, and implements effective needs-based training pertaining to public health laboratory methodology and technology; (3) evaluates the efficiency and effectiveness of public health laboratory education and training for state and local public health, clinical, military, CDC, and other federal agency laboratorians; and (4) evaluates the effectiveness and measures the outcomes of all training to ensure a high quality product for all end users. Delete in its entirety the functional statement for the Division of Leadership and Practice (CPLC) within the Scientific Education and Professional Development Program Office (CPL). Office of Surveillance, Epidemiology and Laboratory Services (CP) and insert the following:

Division of Leadership and Practice (CPLC).

(1) Plans, directs, and manages CDC-wide training and service programs for the teaching and training of public health professionals in public health practice, including public health leadership and management, public policy, program planning, implementation, and evaluation; (2) plans, directs, and manages CDC-wide training and service programs for fellowships and internships sponsored by other partner organizations and implemented within CDC (e.g., Emerging Leaders Program, Presidential Management Internship Program, Association of Schools of Public Health Fellowship); (3) incorporates principles of adult learning theory and current learning standards into the design, delivery, and evaluation of education and training products; (4) leads content development and implementation of workforce development programs; (5) responds to domestic and international requests for assistance and consultation (Emergency Operations Center deployment); (6) maintains knowledge of continuing education standards to uphold national accreditations and provides guidance and consultation, incorporating principles of adult learning theory with course developers to ensure educational activities are accredited for continuing education; (7) works with partner agencies to articulate and build curricula for public health workforce competencies in leadership and management; (8) maintains liaison with other governmental agencies, academic institutions and organizations, state and local health agencies, private health organizations, professional organizations, and other outside groups; (9) provides technical assistance, consultation, resources and training for SEPDPO, other CDC fellowships, and the broader health workforce, including, but not limited to the development and dissemination of standard curricula, training, and related materials, in leadership and management; (10) develops and maintains appropriate internal and external partnerships to foster best practices in the design and delivery of educational activities and training; and (11) coordinates, as appropriate, with the CDC OD, other CIOs, and domestic and international agencies to carry out the functions of the division.

Following the title and functional statement for the Public Health Prevention Service Branch (CPLCC), insert the following:

Educational Design and Accreditation Branch (CPLCD).

(1) Provides consultation, guidance, and technical assistance to course developers, incorporating principles of learning theory to ensure consistent design and delivery of accredited educational activities; (2) maintains knowledge of continuing education standards and applies quality assurance practices required to uphold national accreditations; (3) assesses need and demand for additional accreditations to support professional license and certification needs of technical and professional staff within the health workforce; (4) develops and maintains internal and external partnerships to foster best practices in the design and delivery of educational activities and training.
delivery of educational activities and training; (5) maintains knowledge of information technology and learning standards as they apply to education and training to demonstrate and promote compliance and best practices by CDC programs; (6) applies the principles of instructional systems design and learning theory to design, develop, deliver, and evaluate informational and instructional products; (7) implements and maintains the CDC Training and Continuing Education Online web-based accreditation and registration system; (8) adapts information systems and processes to reflect current best practices and adhere to accreditation requirements; and (9) provides technical assistance and guidance to learners to ensure accreditation and learner support.

Delete in its entirety the title and functional statement for the Division of Training Development and Services (CPD) within the Scientific Education and Professional Development Program Office (CPL), Office of Surveillance, Epidemiology and Laboratory Services (CP).

Dated: March 10, 2011.

James D. Seligman,
Acting Chief Operating Officer, Centers for Disease Control and Prevention.

[FR Doc. 2011–6515 Filed 3–21–11; 8:45 am]

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration


Hartech Corporation; Denial Without Prejudice of Food Additive Petition

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is denying a food additive petition (FAP 1M4246) proposing that the food additive regulations be amended to provide for the safe use of a source of ionizing radiation to treat shellfish, including crustaceans.

DATES: This order is effective June 20, 2011; except as to any provisions that may be stayed by the filing of proper objections. Submit either electronic or written objections and requests for a hearing by April 21, 2011.

ADDRESSES: You may submit either electronic or written objections and requests for a hearing identified by Docket No. FDA–1991–F–0203, by any of the following methods:

Electronic Submissions

Submit electronic objections in the following way:


Written Submissions

Submit written objections in the following ways:

Fax: 301–827–6870.

Mail/Hand delivery/Courier (for paper, disk, or CD–ROM submissions): Division of Dockets Management (HFA–305), Food and Drug Administration, 5630 Fishers Lane, Room 1061, Rockville, MD 20852.


SUPPLEMENTARY INFORMATION: In a notice published in the Federal Register of April 16, 1991 (56 FR 15373), FDA announced that a food additive petition (FAP 1M4246) had been filed by Hartech Corp. (formerly United States Harvest Technologies, Inc., One East Chase St., suites 1112 and 1113, Baltimore, MD). The petition proposed to amend the food additive regulations in § 179.26 Ionizing radiation for the treatment of food (21 CFR 179.26) to provide for the safe use of a source of ionizing radiation to treat shellfish, including crustaceans.

For any food additive petition, the burden is on the petitioner to submit to FDA data and information that are adequate for the Agency to determine that the proposed use of the additive under the specified conditions of use is safe (21 U.S.C. 348(c)(3)(A), 21 CFR 171.1). Hartech Corp. was notified of significant deficiencies in the information supporting its petition by letters from the Agency dated May 28, 1992, February 5, 1999, December 15, 2004, March 19, 2009, and May 22, 2009. The deficiencies related primarily to concerns about the possibility of Clostridium botulinum outgrowth in irradiated products, especially where the normal growth pattern of typical spoilage organisms could be changed by irradiation, thus reducing perception of spoilage. FDA had therefore requested information on typical spoilage and pathogenic microbial populations of shellfish irradiated at the maximum dose requested. FDA also requested additional data on the efficacy of the proposed doses of irradiation in reducing pathogens in crustaceans because the petition only included data on the efficacy of irradiation in reducing the levels of Vibrio species in oysters.

Hartech Corp. has not provided information to address these deficiencies, and the Agency’s most recent letters to Hartech Corp.’s last known address were returned as undeliverable. Additional efforts to contact this petitioner have been unsuccessful. The petitioner has not provided sufficient data and information for the Agency to conclude that the proposed use of the food additive is safe in accordance with section 409 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 348). FDA is therefore denying the petition without prejudice to a future filing (21 U.S.C. 340(c)(1)(B), 21 CFR 171.100(a)).

This order is effective as shown in the DATES section of this document; except as to any provisions that may be stayed by the filing of proper objections. Any person who will be adversely affected by this order may file with the Division of Dockets Management (see ADDRESSES) either electronic or written objections. Each objection shall be separately numbered, and each numbered objection shall specify with particularity the provisions of the regulation to which objection is made and the grounds for the objection. Each numbered objection on which a hearing is requested shall specifically state failure to request a hearing for any particular objection shall constitute a waiver of the right to a hearing on that objection. Each numbered objection for which a hearing is requested shall include a detailed description and analysis of the specific factual information intended to be presented in support of the objection in the event that a hearing is held. Failure to include such a description and analysis for any particular objection shall constitute a waiver of the right to a hearing on the objection. It is only necessary to send one set of documents. It is no longer necessary to send three copies of all documents. Identify documents with the docket number found in brackets in the heading of this document. Any objections received in response to the order may be seen in the Division of Dockets Management between 9 a.m. and 4 p.m., Monday through Friday. FDA will publish notice of the objections that the Agency has received or lack thereof in the Federal Register.

Dated: March 15, 2011.

Leslie Xue,
Acting Assistant Commissioner for Policy.

[FR Doc. 2011–6624 Filed 3–21–11; 8:45 am]